ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

Åke Borg; Bo Baldetorp; Mårten Fernö; Dick Killander; Håkan Olsson; Stefan Ryden; Helgi Sigurdsson

doi:10.1016/0304-3835(94)90194-5

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

Åke Borg^*, Bo Baldetorp, Mårten Fernö, Dick Killander, Håkan Olsson, Stefan Ryden, Helgi Sigurdsson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

229 Citations (Scopus)

Abstract

Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.

Original language	English
Pages (from-to)	137-144
Number of pages	8
Journal	Cancer Letters
Volume	81
Issue number	2
DOIs	https://doi.org/10.1016/0304-3835(94)90194-5
Publication status	Published - 30 Jun 1994

Bibliographical note

Funding Information:
This study was supported by grants from the Swedish Cancer Society, the Swedish Medical Re-searchC ouncil, the Hospital of Lund Foundation, the Lund University Medical Faculty Foundations, the Mrs Bert Kamprad Cancer Foundation, the Gunnar, Arvid and Elisabeth Nilsson Cancer Foundation, the Thelma Zoega Foundation, and the CTRF.

Other keywords

Adjuvant tamoxifen
Breast cancer
ERBB2
Gene amplification
HER-2/neu
Therapy resistance

Access to Document

10.1016/0304-3835(94)90194-5

Cite this

@article{e700cf0b63fb402194e2103f4c9514e4,

title = "ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer",

abstract = "Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.",

keywords = "Adjuvant tamoxifen, Breast cancer, ERBB2, Gene amplification, HER-2/neu, Therapy resistance",

author = "{\AA}ke Borg and Bo Baldetorp and M{\aa}rten Fern{\"o} and Dick Killander and H{\aa}kan Olsson and Stefan Ryden and Helgi Sigurdsson",

note = "Funding Information: This study was supported by grants from the Swedish Cancer Society, the Swedish Medical Re-searchC ouncil, the Hospital of Lund Foundation, the Lund University Medical Faculty Foundations, the Mrs Bert Kamprad Cancer Foundation, the Gunnar, Arvid and Elisabeth Nilsson Cancer Foundation, the Thelma Zoega Foundation, and the CTRF.",

year = "1994",

month = jun,

day = "30",

doi = "10.1016/0304-3835(94)90194-5",

language = "English",

volume = "81",

pages = "137--144",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

AU - Borg, Åke

AU - Baldetorp, Bo

AU - Fernö, Mårten

AU - Killander, Dick

AU - Olsson, Håkan

AU - Ryden, Stefan

AU - Sigurdsson, Helgi

N1 - Funding Information: This study was supported by grants from the Swedish Cancer Society, the Swedish Medical Re-searchC ouncil, the Hospital of Lund Foundation, the Lund University Medical Faculty Foundations, the Mrs Bert Kamprad Cancer Foundation, the Gunnar, Arvid and Elisabeth Nilsson Cancer Foundation, the Thelma Zoega Foundation, and the CTRF.

PY - 1994/6/30

Y1 - 1994/6/30

N2 - Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.

AB - Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.

KW - Adjuvant tamoxifen

KW - Breast cancer

KW - ERBB2

KW - Gene amplification

KW - HER-2/neu

KW - Therapy resistance

UR - http://www.scopus.com/inward/record.url?scp=0028360192&partnerID=8YFLogxK

U2 - 10.1016/0304-3835(94)90194-5

DO - 10.1016/0304-3835(94)90194-5

M3 - Article

C2 - 7912163

AN - SCOPUS:0028360192

SN - 0304-3835

VL - 81

SP - 137

EP - 144

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

Abstract

Bibliographical note

Other keywords

Access to Document

Fingerprint

Cite this